Cataract Surgery with Alcon's AcrySof IQ Vivity IOLs Demonstrates Sustained High Patient Satisfaction and Reduced Spectacle Dependence

The Alcon Vivity Registry is still showing impressive results with the AcrySof IQ Vivity and AcrySof IQ Vivity Toric, which are the only lenses on the market that feature wavefront-shaping technology. Some of the most famous surgeons in the world will be sharing the latest data from the registry at ESCRS2023, and this includes information about visual disturbances rates. The registry has been keeping tabs on over 900 cataract patients after they underwent surgery, even those with some minor health conditions.

Alcon, a company that helps people see better, has released new information from its Vivity® Registry Study. This study looks at the experiences of real patients who have had cataract surgery and received one of two kinds of intraocular lenses (IOLs): AcrySof® IQ Vivity® or AcrySof® IQ Vivity® Toric presbyopia-correcting IOLs. The data collected from over 900 patients shows that both types of IOLs continued to work well for up to a year after surgery. Patients were also very happy with the results and needed glasses less often. The information also indicates that AcrySof® IQ Vivity® can be used in many different kinds of patients, giving doctors and patients more choices for treatment.

The AcrySof® IQ Vivity® has been a game changer since it came out, and we are extremely proud of it as a company. This innovative technology is built with a special X-WAVETM technology that stretches and shifts light, without diffusing it. Sunil Vasanth, VP of the Europe Surgical Franchise at Alcon, expressed his excitement about Vivity®, calling it the first of its kind in the world. Thanks to our real-world data registry, doctors can be sure that Vivity® will perform well over time, even with patients who have mild health issues such as glaucoma, dry eye, and retinopathy/maculopathy.

The Vivity® Registry Study3 was undertaken across 41 sites in eight (8) countries, namely Australia, Belgium, Germany, New Zealand, the Netherlands, Portugal, Spain, and the United Kingdom. As a multicentre, ambispective, non-comparative, open-label, non-interventional registry study, it provided a lot of data for analysis. At the end of the study, the researchers made some findings.3

The outcomes and extra information are currently being talked about by famous surgeons from around the globe in 11 meetings at the 41st ESCRS Conference, occurring in Vienna, Austria. To get more details on the important summaries, go to MyAlconatESCRS.com.

AcrySof® IQ Vivity® is a type of lens that doesn't diffract light. It uses a special technology called Wavefront-Shaping X-WAVE™, which is different from older methods that split light into different directions. This lens is great because it helps people see clearly at different distances, including up close for daily tasks like using a phone. It also doesn't cause many visual disruptions. Overall, AcrySof® IQ Vivity® is really helpful for people who need clear vision all the time.

As individuals age, their focus on vision becomes a top priority, and medical professionals such as surgeons can significantly impact their overall eye health.

A recent global survey conducted by Alcon has found that vision is considered one of the most important aspects of ageing, ranking second alongside mobility at 83%. Only memory ranked higher at 84%. For those who have been diagnosed with cataracts, vision is the biggest concern when it comes to ageing. The survey found that after receiving surgery, cataract patients reported a significant improvement in their quality of life, with 81% of patients who received any PCIOL experiencing this positive outcome. The survey also revealed that 69% of those surveyed who hadn't been diagnosed with cataracts would feel more liberated if they didn't have to wear glasses. Among those who were awaiting cataract surgery, three out of four said they would be willing to pay for a lens that removes the need for glasses.

Having a clear perspective can greatly inspire seniors as they mature. The AcrySof® IQ Vivity® can fulfill the needs and wants of patients when it comes to their abilities, standard of living and the ability to see clearly without any aids.

The approval of AcrySof® IQ Vivity® and AcrySof® IQ Vivity® Toric may vary in different markets. You can contact your Alcon Rep if you want to know whether they are available in your area. For a full list of indications, contraindications, and warnings, please consult the relevant product DFU or Operator's manuals.

This information is specific to individuals who work in the healthcare field. It's important to keep in mind that raising awareness about medical devices amongst non-healthcare professionals might not be allowed, and it may be regulated according to local guidelines.

The AcrySof® IQ Vivity® IOL is a revolutionary new intraocular lens that has been designed to improve the vision of individuals with cataracts. It is made from a unique material that allows it to bend and flow with the natural movements of the eye, providing clearer and more natural vision. The lens also has a special design that allows it to correct for both near and distance vision, offering a wider range of clear vision for patients. With its advanced technology and innovative design, the AcrySof® IQ Vivity® IOL is quickly becoming the preferred choice for cataract surgery patients who want the best possible visual outcomes.

The AcrySof® IQ Vivity® IOL is a type of foldable lens inserted into the eye's posterior chamber. It is different from a regular lens because it is non-diffractive and has the ability to absorb UV rays and filter blue light. What's special about the AcrySof® IQ Vivity® IOL is that it has an extended range of vision, meaning it can help with both near and distant vision. Unlike a regular lens, it won't cause any visual disturbances.

Risks to be aware of: Surgery always carries some risks, even with an IOL implant. These risks can range from minor, temporary side effects to more serious complications. People who have underlying medical conditions like eye or eyelid infections or diabetes may be more prone to complications. Some possible temporary complications include reactions to medication, such as mild allergic reactions or irritation, bleeding, feeling of itchiness, sensitivity to light, swelling, or swelling of the cornea. Other risks include problems with the iris, cell growth in the IOL, or temporary high eye pressure. There is a slight chance that additional surgery may be needed, such as the replacement of the initial IOL or a procedure to enhance visual acuity.

Alcon is the best in the world in the field of eye care. With its history of over 75 years, Alcon is known for its wide range of products that help people see better and ultimately live better lives. We offer products and services which help those living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors in over 140 countries worldwide, touching the lives of more than 260 million people each year. At present, our team consists of more than 25,000 skilled professionals who are constantly working towards improving the lives of people through innovative products, working with Eye Care Professionals and ensuring access to quality eye care through various programs. If you want to know more about Alcon and our services please visit www.alcon.com.

The CATQUEST 9SF questionnaire was used to assess the satisfaction of subjects who had the Presbyopia Correcting Intraocular Lens. The questionnaire asked patients if they experienced difficulty with their vision while performing activities, and if so, to what degree. The satisfaction of the subjects was categorized as either "very" or "fairly" satisfied. Open, non-prompted questions were also asked to evaluate any visual disturbances experienced by the patients. Another survey called IOLSAT asked patients how often they needed to wear eyeglasses in the past week to see clearly. The Alcon Eye on Cataract survey conducted between March and April 2023 evaluated vision and cataract insights among the aging population in Australia, Brazil, China, Germany, India, Italy, Japan, Spain, South Korea, and the United States. The survey included 7,331 participants, including 1,826 pre- and post-cataract surgery patients aged 50+ who had received their diagnosis within the last five years (both monofocal and multifocal intraocular lens recipients), and 5,505 people aged 50+ who had not been diagnosed with cataract(s) and who had not undergone surgery.

Join us on Facebook and LinkedIn X to stay connected.

You can see the original version of this article at businesswire.com by following the link: https://www.businesswire.com/news/home/20230908619997/en/